

APR 1 2 2004

K040336  
page 1 of 1

**3. 510(k) Summary:**

**Sponsor:** Synthes (USA)  
1690 Russell Road  
Paoli, PA 19301  
(610) 647-9700

**Contact:** Sheri L. Musgnung

**Device Name:** Synthes (USA) Lateral Entry Femoral Nail System

**Device Classification:** 21 CFR 888.3020 – “Intramedullary fixation rod”  
21 CFR 888.3040 – “Smooth or threaded metallic bone fixation fastener”

**Predicate Device:** Synthes Ti Cannulated Femoral Nail, Smith & Nephew TriGen Antegrade Femoral Nail and DePuy ACE ART Femoral Nail.

**Description of Device:** Synthes Lateral Entry Femoral Nail System is composed of cannulated femoral nails, solid 6.5 mm recon locking screws and cannulated end caps. Recon locking screws, as well as Synthes commercially available 5.0 mm and 6.0 mm locking screws, are used to secure the nail in the bone.

**Indications:** Synthes Lateral Entry Femoral Nail System is intended to stabilize femoral shaft fractures, subtrochanteric fractures, ipsilateral neck/shaft fractures, impending pathologic fractures, non-unions and malunions.

**Material:** Titanium alloy

**Substantial Equivalence:** Documentation is provided which demonstrates that the Synthes Lateral Entry Femoral Nail System is substantially equivalent\* to other legally marketed devices.

\* The term “substantially equivalent” as used in this 510(k) notification is limited to the definition of substantial equivalence found in the Food, Drug, and Cosmetic Act, as amended and as applied under 21 CFR 807, Subpart E, under which a device can be marketed without pre-market approval or reclassification. A determination of substantial equivalency under this notification is not intended to have any bearing whatsoever on the resolution of patent infringement suits or any other patent matter. No statements related to, or in support of substantial equivalence herein shall be construed as an admission against interest under the US Patent Laws or their application by the courts.

CONFIDENTIAL



Food and Drug Administration  
9200 Corporate Boulevard  
Rockville MD 20850

APR 1 2 2004

Ms. Sheri L. Musgnung  
Regulatory Affairs Specialist  
Synthes (USA)  
1690 Russell Road  
Post Office Box 1766  
Paoli, Pennsylvania 19301

Re: K040336  
Trade/Device Name: Synthes (USA) Lateral Entry Femoral Nail System  
Regulation Number: 21 CFR 888.3020  
Regulation Name: Intramedullary fixation rod  
Regulatory Class: II  
Product Code: HSB  
Dated: February 10, 2004  
Received: February 11, 2004

Dear Ms. Musgnung:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.


Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Page 2 – Ms. Sheri L. Musgnung

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (301) 594-4659. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <http://www.fda.gov/cdrh/dsma/dsmamain.html>

Sincerely yours,

A handwritten signature in black ink, appearing to read "Celia M. Witten". The signature is written in a cursive style and is positioned above the typed name.

Celia M. Witten, Ph.D., M.D.  
Director  
Division of General, Restorative  
and Neurological Devices  
Office of Device Evaluation  
Center for Devices and  
Radiological Health

Enclosure

